The LATTICE Clinical Trial and the Evolving Search for Lithium-Based Alzheimer’s Therapeutics

For over two decades, the scientific community has pursued a compelling, albeit elusive, hypothesis: that lithium—a mood-stabilizing element long utilized in psychiatric medicine—might serve as a disease-modifying treatment for Alzheimer’s disease (AD). This pursuit reached a critical juncture with the recent publication of the Lithium as a Treatment to prevent Impairment of Cognition in Elders (LATTICE) trial in JAMA Neurology. The study, which investigated the impact of low-dose lithium carbonate on individuals with mild cognitive impairment (MCI), reported that the intervention failed to meet its six primary clinical endpoints. However, the nuance buried within the trial’s data suggests that the narrative of "failure" is premature, highlighting instead the immense complexity of clinical trial design, target engagement, and the potential for alternative lithium formulations to reshape future research.

The Long Road to LATTICE: A Chronology of Investigation

The conceptual foundation for LATTICE was built upon layers of observational and mechanistic evidence. Since the early 2000s, researchers have noted an "ecological" signal: populations residing in regions with higher concentrations of lithium in their municipal drinking water consistently exhibit lower incidences of dementia and Alzheimer’s. While these observational studies are inherently limited by confounding variables, they provided the initial impetus for exploring lithium’s neuroprotective potential.

Concurrently, clinical data from patients with bipolar disorder (BPD) treated with long-term lithium therapy revealed a consistent, intriguing pattern. These patients often demonstrated reduced rates of dementia compared to their peers, along with structural brain benefits, such as preserved hippocampal volume and improved integrity of white matter. These observations led to early, small-scale clinical trials that yielded promising, if sometimes conflicting, results. For instance, studies by Forlenza et al. in the early 2010s suggested that low-dose lithium could slow cognitive decline in patients with amnestic MCI. These studies were particularly notable for measuring biomarkers, observing that lithium treatment seemed to influence the clearance of beta-amyloid and reduce abnormal tau protein—the two molecular hallmarks of Alzheimer’s pathology.

By the time the LATTICE trial, led by Dr. Ariel Gildengers at the University of Pittsburgh, was designed, the objective was to provide a definitive, rigorous evaluation of these findings. The trial randomized 80 participants aged 60 and older with MCI to receive either low-dose lithium carbonate or a placebo over a two-year period.

Understanding the Null Results

The headline findings of the LATTICE trial were, by all accounts, disappointing. None of the six prespecified primary endpoints—which included verbal memory, visuospatial memory, composite cognitive scores, hippocampal volume, cortical gray matter volume, and plasma BDNF—reached the required threshold for statistical significance.

However, a critical re-examination of the study parameters suggests several factors that likely compromised the trial’s ability to detect a true therapeutic signal. Most notably, the trial population was remarkably heterogeneous. Approximately 75% of the participants did not possess the beta-amyloid pathology necessary for an Alzheimer’s diagnosis. If lithium’s mechanism of action is indeed specific to the pathophysiology of AD—such as inhibiting glycogen synthase kinase 3-beta (GSK-3β) to prevent amyloid aggregation—then testing the drug in a cohort lacking that pathology is statistically akin to testing a targeted cancer therapy on patients who do not have the specific cancer marker.

Furthermore, the issue of dosing remains a central point of contention. The LATTICE trial utilized a dose of lithium carbonate that resulted in serum levels of approximately 0.17 mEq/L. This is significantly lower than the levels utilized in studies that previously reported cognitive benefits. This "Goldilocks" dilemma—finding a dose high enough to be therapeutic but low enough to avoid the cognitive impairment and side effects associated with high-dose lithium—remains the greatest challenge for researchers. If the dose is too low to reach the brain’s therapeutic threshold, the result is a null finding that obscures the drug’s potential utility.

The Emerging Promise of Lithium Orotate

While LATTICE utilized lithium carbonate, recent mechanistic research has shifted the focus toward alternative salts, specifically lithium orotate. A landmark paper published in Nature by Aron et al. in 2025 offered a compelling explanation for why standard lithium carbonate might be failing in clinical trials.

The researchers discovered that in the brains of patients with MCI and AD, lithium is not systemically deficient, but rather sequestered—trapped inside the very beta-amyloid plaques it is intended to combat. The study demonstrated that inorganic salts like lithium carbonate dissociate into lithium ions too readily, making them highly susceptible to the "magnetic" attraction of negatively charged amyloid plaques. In contrast, lithium orotate, which is less polar, can penetrate brain tissue more effectively and deliver the lithium ion to neurons before it becomes bound by plaque structures. In mouse models, lithium orotate proved significantly more effective than the carbonate form at a fraction of the dosage, providing a pathway to potentially overcome the dosing paradox that hindered LATTICE.

Implications for Future Research

The failure of the LATTICE trial to produce a "home run" result has not dampened the scientific interest in lithium; rather, it has clarified the requirements for the next generation of trials. Experts in the field, including those commenting on the JAMA Neurology findings, argue that the "shotgun approach" of past trials must be replaced by a precision medicine model.

Future research will likely prioritize three key pillars:

1. Biomarker-Driven Enrollment: Utilizing modern diagnostic tools, such as plasma ptau217 tests, to ensure that every participant in a trial has confirmed beta-amyloid pathology. This eliminates the "dilution effect" that plagued LATTICE, ensuring that the drug is only evaluated in the specific patient population it is intended to help.
2. Pharmacodynamic Dose-Ranging: Before embarking on large-scale, multi-year efficacy trials, researchers must conduct rigorous dose-ranging studies to determine exactly what serum levels are required to achieve target engagement—specifically measuring the inhibition of GSK-3β and the modulation of BDNF levels in human subjects.
3. Head-to-Head Formulation Comparisons: There is an urgent need for clinical trials that directly compare lithium carbonate against lithium orotate. While the orotate salt has shown significant potential in preclinical models, its safety and efficacy in humans remain hypothetical.

The Broader Societal and Medical Context

The current landscape of Alzheimer’s research is in a state of rapid transition. As anti-amyloid antibodies like lecanemab and donanemab gain regulatory approval, the focus is shifting toward combination therapies and preventative measures. Lithium, being a low-cost, off-patent substance, lacks the financial backing of major pharmaceutical companies, which creates a significant hurdle for funding the large-scale, multicenter trials required to achieve definitive proof.

As Dr. Orestes Forlenza, a lead researcher in the field, has noted, the infrastructure required to run a high-quality, long-term Alzheimer’s prevention trial is immense. Without a commercial sponsor, this burden falls on public health agencies and academic institutions. Despite these logistical barriers, the persistent, consistent signal across observational, mechanistic, and small-scale experimental data remains too strong to ignore.

A Note on Self-Experimentation

The publication of the Nature paper and the subsequent media interest have led to a significant surge in the use of over-the-counter lithium orotate. Market reports indicate that the lithium orotate supplement sector is experiencing substantial growth. However, medical professionals strongly caution against the current trend of widespread self-experimentation.

While standard low-dose dietary lithium is generally considered safe, there is a lack of data regarding the long-term, high-dose safety profile of orotate in older adults who may have other underlying conditions or be taking other medications. The existence of international databases documenting adverse events associated with lithium supplements underscores the necessity of clinical oversight. For the time being, the consensus remains that while lithium is a high-priority area for medical investigation, it should not be viewed as a proven preventative supplement for cognitive decline.

Conclusion: The Path Forward

The LATTICE trial serves as a vital lesson in the evolution of Alzheimer’s therapeutics. It demonstrates that a "negative" result in a clinical trial is not necessarily an end, but a refinement of the scientific inquiry. By highlighting the necessity of patient selection, the impact of molecular sequestration, and the potential superiority of different chemical formulations, LATTICE has provided a roadmap for what a successful trial might look like.

As the scientific community moves forward, the focus must remain on objective, rigorous, and biomarker-led research. The goal is no longer to ask if "lithium works for Alzheimer’s," but rather to identify the specific formulation, dosage, and patient population that will allow the drug to exert its neuroprotective effects before the disease process has reached an irreversible stage. Until such trials are conducted and reported, the promise of lithium remains a tantalizing possibility—one that demands the patience and discipline of the scientific method rather than the speed of consumer demand.